| Patient | Pablo Neruda |
|---|---|
| Date of birth | 1904-07-12 |
| Identifiers | MRN HR-ML051-SYN-TD; SSN (made up) 000-51-2976 |
| Document date | 2026-11-01 |
| Author | Marisol Fairweather-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referral. Concerns: He wants to know what the pain and the urinary symptoms mean, and to be told plainly; He wants to keep writing every morning and to carry on his duties as ambassador; He wants important discussions held in Spanish. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1966-04-06 to 1971-07-13 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1971-07-13 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain | Two tablets up to three times daily as needed | Oral route | 1971-06-01 to 1971-09-14 | completed | S |
| Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food | One tablet once daily | Oral route | 1971-06-15 | active | S |
| Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks | One injection every twelve weeks | Intramuscular route | 1971-06-22 | active | S |
| Cholecalciferol (vitamin D3) 1945 units (0.05 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 1971-06-15 | active | S |
| Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation | One injection every six months | Subcutaneous route | 1971-07-13 | active | S |
| Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin) | Twice daily for two weeks | Topical route | 1971-08-10 to 1971-08-24 | completed | S |
| Cetirizine 10 mg oral tablet, one tablet daily for itch | One tablet daily | Oral route | 1971-08-10 to 1971-08-31 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1971-10-05 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Multiparametric MRI of the prostate: gland 52 mL; 24 mm PI-RADS 5 lesion in the right peripheral zone from mid-gland to base with extraprostatic extension on the right; no seminal vesicle invasion; 13 mm right external iliac lymph node; abnormal marrow signal in the right iliac bone at the edge of the field | 1971-06-03 to 1971-06-03 | completed | S |
| CT of the chest, abdomen and pelvis with contrast: enlarged right external iliac (13 mm) and right obturator (11 mm) lymph nodes; sclerotic lesions in the right iliac wing and the L5 vertebral body without a soft-tissue mass or canal narrowing; no lung, liver or adrenal lesions | 1971-06-04 to 1971-06-04 | completed | S |
| Whole-body bone scan (technetium-99m): two foci of increased uptake, in the right iliac wing and L5, matching the CT; no other skeletal lesions (fewer than four bone metastases, all in the spine and pelvis: low volume) | 1971-06-04 to 1971-06-04 | completed | S |
| MRI-ultrasound fusion transperineal biopsy of the prostate, at the urology practice: adenocarcinoma, Gleason 4+4 (Grade Group 4) in 3 of 3 targeted cores (up to 80 percent of the core) and Gleason 4+4 or 4+3 in 6 of 12 systematic cores, all on the right; 9 of 14 cores in all; perineural invasion present; no intraductal or neuroendocrine features | 1971-06-08 to 1971-06-08 | completed | S |
| Gallium-68 PSMA PET/CT: intense uptake in the right side of the prostate, in the right external iliac and right obturator nodes, and in the right iliac wing and L5; no other nodal, bone or visceral disease | 1971-06-11 to 1971-06-11 | completed | S |
| Bone densitometry (DXA) of the hip and lumbar spine before androgen deprivation; L5 excluded because of a metastasis | 1971-06-15 to 1971-06-15 | completed | S |
| Image-guided intensity-modulated radiotherapy to the prostate, 55 Gy in 20 daily fractions over four weeks, for low-volume metastatic disease; no pelvic nodal or bone radiation | 1971-07-27 to 1971-08-21 | completed | S |
| Advance care planning conversation, about 30 minutes, in Spanish with a professional interpreter, with his consent | 1971-10-05 to 1971-10-05 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1965-09-21 | Tdap vaccine | completed | S |
| 1970-10-14 | High-dose influenza vaccine, last season | completed | S |
| 1971-10-05 | High-dose influenza vaccine, this season | completed | S |
| 1971-10-05 | COVID-19 vaccine, mRNA, this season | completed | S |
| 1971-10-05 | Pneumococcal conjugate vaccine PCV20 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died shortly after his birth; cause not recorded in the cited source | D (CLM-0001) |
| Concern | Status | Evidence |
|---|---|---|
| He wants to know what the pain and the urinary symptoms mean, and to be told plainly | active | S |
| He wants to keep writing every morning and to carry on his duties as ambassador | active | S |
| He wants important discussions held in Spanish | active | S |
Most recent measures: Prostate specific Ag [Mass/volume] in Serum or Plasma 0.18 on 1971-09-14; Testosterone [Mass/volume] in Serum or Plasma 14 on 1971-09-14; Hemoglobin [Mass/volume] in Blood 12.9 on 1971-09-14; Leukocytes [#/volume] in Blood by Automated count 5.9 on 1971-09-14; Platelets [#/volume] in Blood by Automated count 231 on 1971-09-14; Sodium [Moles/volume] in Serum or Plasma 140 on 1971-09-14; Potassium [Moles/volume] in Serum or Plasma 4.5 on 1971-09-14; Glucose [Mass/volume] in Serum or Plasma 102 on 1971-09-14; Creatinine [Mass/volume] in Serum or Plasma 0.99 on 1971-09-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M 83 on 1971-09-14; Calcium [Mass/volume] in Serum or Plasma 9.2 on 1971-09-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1971-09-14; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1971-09-14; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 96 on 1971-09-14; Albumin [Mass/volume] in Serum or Plasma 4 on 1971-09-14; Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma 208 on 1971-06-01; Hemoglobin A1c/Hemoglobin.total in Blood 6.1 on 1971-09-14; Cholesterol [Mass/volume] in Serum or Plasma 214 on 1971-06-01; Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 on 1971-06-01; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 140 on 1971-06-01; Triglyceride [Mass/volume] in Serum or Plasma 140 on 1971-06-01; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 28 on 1971-07-13; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 1971-06-01; International Prostate Symptom Score [IPSS] 9 on 1971-09-14; Pain severity - 0-10 verbal numeric rating [Score] - Reported 1 on 1971-09-14; DXA Femur [T-score] Bone density -2.1 on 1971-06-15; DXA Lumbar spine [T-score] Bone density -1.4 on 1971-06-15; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1971-10-05; Thyrotropin [Units/volume] in Serum or Plasma 5.4 on 1971-09-14; Eosinophils [#/volume] in Blood by Automated count 0.3 on 1971-08-10; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1 on 1971-09-14; Total score [Mini-Cog] 5 on 1971-10-05; Total score [AUDIT-C] 2 on 1971-10-05 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed | resolved | confirmed | R97.20 | S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer. |
| Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1916 | active | confirmed | C61 | S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read. |
| Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites. |
| Pelvic lymph node metastases: right external iliac and right obturator nodes | active | confirmed | C77.5 | S — Synthetic nodal disease. |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition | active | confirmed | Z79.899 | S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| Essential hypertension for five years, on amlodipine | active | confirmed | I10 | S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure. |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding at intake, addressed at the second visit. |
| Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis) | active | confirmed | M85.89 | S — Synthetic bone-health finding on the DXA before androgen deprivation. |
| Prediabetes (hemoglobin A1c 5.9%) | active | confirmed | R73.03 | S — Synthetic metabolic finding at intake, relevant to androgen deprivation. |
| Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamide | resolved | confirmed | L27.0 | S — Synthetic intercurrent problem at an unscheduled visit; a known effect of apalutamide, not a historical claim. |
| Personal history of radiotherapy to the prostate (55 Gy in 20 fractions, finished three weeks before the three-month visit) | active | confirmed | Z92.3 | S — Synthetic: recorded after the course of radiotherapy finished. |
| Raised TSH (5.4 mIU/L) with a normal free T4 on apalutamide: subclinical, under observation | active | confirmed | R94.6 | S — Synthetic finding; raised TSH is a known effect of apalutamide. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1971-06-01 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 46.8 | ng/mL | <=4 ng/mL | High | S |
| 1971-06-01 | Testosterone [Mass/volume] in Serum or Plasma | 468 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Normal | S |
| 1971-06-01 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1971-06-01 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1971-06-01 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1971-06-01 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1971-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1971-06-01 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 1971-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1971-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1971-06-01 | Calcium [Mass/volume] in Serum or Plasma | 9.6 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1971-06-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 1971-06-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-48 U/L | Normal | S |
| 1971-06-01 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 168 | U/L | 40-129 U/L | High | S |
| 1971-06-01 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 1971-06-01 | Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma | 208 | U/L | 135-225 U/L | Normal | S |
| 1971-06-01 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9 | % | <=5.6% | High | S |
| 1971-06-01 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 1971-06-01 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 1971-06-01 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 140 | mg/dL | <=129 mg/dL | High | S |
| 1971-06-01 | Triglyceride [Mass/volume] in Serum or Plasma | 140 | mg/dL | <=149 mg/dL | Normal | S |
| 1971-06-01 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |
| 1971-06-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1971-06-01 | International Prostate Symptom Score [IPSS] | 17 | {score} | S | ||
| 1971-06-01 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S | ||
| 1971-06-15 | DXA Femur [T-score] Bone density | -2.1 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 1971-06-15 | DXA Lumbar spine [T-score] Bone density | -1.4 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 1971-06-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1971-06-15 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S | ||
| 1971-07-13 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 6.2 | ng/mL | <=4 ng/mL | High | S |
| 1971-07-13 | Testosterone [Mass/volume] in Serum or Plasma | 22 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Low | S |
| 1971-07-13 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1971-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1971-07-13 | Glucose [Mass/volume] in Serum or Plasma | 101 | mg/dL | 70-99 mg/dL | High | S |
| 1971-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1971-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M | 85 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1971-07-13 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1971-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 | U/L | 7-55 U/L | Normal | S |
| 1971-07-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 8-48 U/L | Normal | S |
| 1971-07-13 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 141 | U/L | 40-129 U/L | High | S |
| 1971-07-13 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 1971-07-13 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 28 | ng/mL | 30-100 ng/mL | Low | S |
| 1971-07-13 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 1971-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1971-07-13 | International Prostate Symptom Score [IPSS] | 14 | {score} | S | ||
| 1971-07-13 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 1971-08-10 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1971-08-10 | Eosinophils [#/volume] in Blood by Automated count | 0.3 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 1971-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.97 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1971-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M | 86 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1971-08-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 7-55 U/L | Normal | S |
| 1971-08-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 8-48 U/L | Normal | S |
| 1971-09-14 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 0.18 | ng/mL | <=4 ng/mL | Normal | S |
| 1971-09-14 | Testosterone [Mass/volume] in Serum or Plasma | 14 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Low | S |
| 1971-09-14 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1971-09-14 | Leukocytes [#/volume] in Blood by Automated count | 5.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1971-09-14 | Platelets [#/volume] in Blood by Automated count | 231 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1971-09-14 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1971-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1971-09-14 | Glucose [Mass/volume] in Serum or Plasma | 102 | mg/dL | 70-99 mg/dL | High | S |
| 1971-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.99 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1971-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M | 83 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1971-09-14 | Calcium [Mass/volume] in Serum or Plasma | 9.2 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1971-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 1971-09-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-48 U/L | Normal | S |
| 1971-09-14 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 40-129 U/L | Normal | S |
| 1971-09-14 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 1971-09-14 | Thyrotropin [Units/volume] in Serum or Plasma | 5.4 | m[IU]/L | 0.45-4.5 mIU/L | High | S |
| 1971-09-14 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1971-09-14 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.1 | % | <=5.6% | High | S |
| 1971-09-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1971-09-14 | International Prostate Symptom Score [IPSS] | 9 | {score} | S | ||
| 1971-09-14 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | {score} | S | ||
| 1971-10-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1971-10-05 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 1971-10-05 | Total score [AUDIT-C] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1971-06-01 | Body height | 178 | cm | S |
| 1971-06-01 | Body weight | 92.4 | kg | S |
| 1971-06-01 | Body mass index (BMI) [Ratio] | 29.2 | kg/m2 | S |
| 1971-06-01 | Systolic blood pressure | 146 | mm[Hg] | S |
| 1971-06-01 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 1971-06-01 | Heart rate | 76 | /min | S |
| 1971-06-01 | Respiratory rate | 14 | /min | S |
| 1971-06-01 | Body temperature | 36.7 | Cel | S |
| 1971-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1971-06-15 | Body height | 178 | cm | S |
| 1971-06-15 | Body weight | 92 | kg | S |
| 1971-06-15 | Body mass index (BMI) [Ratio] | 29 | kg/m2 | S |
| 1971-06-15 | Systolic blood pressure | 142 | mm[Hg] | S |
| 1971-06-15 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 1971-06-15 | Heart rate | 74 | /min | S |
| 1971-06-15 | Respiratory rate | 14 | /min | S |
| 1971-06-15 | Body temperature | 36.6 | Cel | S |
| 1971-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1971-07-13 | Body height | 178 | cm | S |
| 1971-07-13 | Body weight | 92.8 | kg | S |
| 1971-07-13 | Body mass index (BMI) [Ratio] | 29.3 | kg/m2 | S |
| 1971-07-13 | Systolic blood pressure | 152 | mm[Hg] | S |
| 1971-07-13 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 1971-07-13 | Heart rate | 76 | /min | S |
| 1971-07-13 | Respiratory rate | 14 | /min | S |
| 1971-07-13 | Body temperature | 36.6 | Cel | S |
| 1971-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1971-08-10 | Body height | 178 | cm | S |
| 1971-08-10 | Body weight | 93 | kg | S |
| 1971-08-10 | Body mass index (BMI) [Ratio] | 29.4 | kg/m2 | S |
| 1971-08-10 | Systolic blood pressure | 136 | mm[Hg] | S |
| 1971-08-10 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1971-08-10 | Heart rate | 80 | /min | S |
| 1971-08-10 | Respiratory rate | 14 | /min | S |
| 1971-08-10 | Body temperature | 36.8 | Cel | S |
| 1971-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1971-09-14 | Body height | 178 | cm | S |
| 1971-09-14 | Body weight | 94.2 | kg | S |
| 1971-09-14 | Body mass index (BMI) [Ratio] | 29.7 | kg/m2 | S |
| 1971-09-14 | Systolic blood pressure | 132 | mm[Hg] | S |
| 1971-09-14 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1971-09-14 | Heart rate | 72 | /min | S |
| 1971-09-14 | Respiratory rate | 14 | /min | S |
| 1971-09-14 | Body temperature | 36.6 | Cel | S |
| 1971-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1971-10-05 | Body height | 178 | cm | S |
| 1971-10-05 | Body weight | 94.6 | kg | S |
| 1971-10-05 | Body mass index (BMI) [Ratio] | 29.9 | kg/m2 | S |
| 1971-10-05 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1971-10-05 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1971-10-05 | Heart rate | 70 | /min | S |
| 1971-10-05 | Respiratory rate | 14 | /min | S |
| 1971-10-05 | Body temperature | 36.6 | Cel | S |
| 1971-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1971-06-01 | New patient with four months of urinary symptoms and six weeks of right hip and low back pain: examination, PSA and baseline tests, pain control, the staging and biopsy plan, and medical oncology referral | finished | S |
| 1971-06-15 | Two-week review with the medical oncology consultation the same day: biopsy and staging results, the diagnosis, shared decision on treatment, the start of apalutamide, genetic testing, and bone density | finished | S |
| 1971-07-13 | Four-week review on apalutamide and leuprolide: early PSA response, testosterone, blood pressure, pain, the dental check and the first denosumab dose, and the radiotherapy plan | finished | S |
| 1971-09-14 | Three-month review: PSA and testosterone, thyroid function, blood count and chemistry, glucose, radiotherapy effects, the rash, the second leuprolide injection, and plans for the year | finished | S |
| 1971-08-10 | Same-day sick visit for an itchy rash on apalutamide | finished | S |
| 1971-10-05 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Medical oncology (genitourinary) consultation within two weeks for suspected metastatic prostate cancer: diagnosis, staging, systemic treatment, radiotherapy, bone health and genetic testing | completed | GL-NCCN-PROSTATE-2026, GL-AUA-APC-2026 | S |
| Diagnosis and staging: multiparametric MRI of the prostate, an MRI-targeted transperineal biopsy at the urology practice, CT of the chest, abdomen and pelvis, a bone scan, and PSMA PET/CT | completed | GL-NCCN-PROSTATE-2026, GL-AUA-APC-2026, GL-CMID-2026 | S |
| Bone pain: acetaminophen 1000 mg up to three times a day; spinal cord compression warning signs explained in Spanish, with same-day assessment for new leg weakness or numbness, or loss of bladder or bowel control | completed | GL-NCCN-PROSTATE-2026 | S |
| Care in Spanish, his first language: a professional medical interpreter for every major discussion, written plans in Spanish, appointments placed around his morning writing and his official duties | completed | GL-NCCN-PROSTATE-2026 | S |
| Systemic therapy: apalutamide 240 mg daily from the consultation day and leuprolide 22.5 mg every twelve weeks from one week later, continuous; docetaxel not added for low-volume disease | completed | GL-AUA-APC-2026, GL-NCCN-PROSTATE-2026, GL-TITAN-2019, GL-CHAARTED-2018 | S |
| Radiotherapy to the prostate, 55 Gy in 20 daily fractions, about six weeks after starting androgen deprivation, for low-volume metastatic disease | completed | GL-AUA-APC-2026, GL-NCCN-PROSTATE-2026, GL-STAMPEDE-H-2018 | S |
| Germline genetic testing with pre-test counseling, and somatic testing of the biopsy tissue | completed | GL-AUA-APC-2026, GL-NCCN-PROSTATE-2026 | S |
| Bone health on androgen deprivation: DXA and FRAX, cholecalciferol 1945 units a day, calcium 1000 to 1200 mg a day from food, weight-bearing exercise, a dental examination, then denosumab 60 mg every six months for high fracture risk; DXA again in one to two years | completed | GL-AUA-APC-2026, GL-CMID-2026, GL-CALGB90202-2014 | S |
| Monitoring on androgen deprivation and apalutamide: PSA and testosterone every three months, blood count and chemistry, TSH every four months, blood pressure at every visit, hemoglobin A1c and lipids, rash, falls, hot flashes, sexual health, fatigue, mood and cognition | completed | GL-CMID-2026, GL-ERLEADA-2026, GL-AUA-APC-2026 | S |
| Apalutamide rash: triamcinolone 0.1% cream twice daily for two weeks, cetirizine 10 mg daily, fragrance-free emollient, continue apalutamide; stop it and call the same day for blisters, peeling, mouth or eye sores, fever, or spread beyond a third of the skin | completed | GL-ERLEADA-2026, GL-NCCN-PROSTATE-2026 | S |
| Atorvastatin 20 mg daily for primary prevention, with a lipid panel and ALT in six to twelve weeks | completed | GL-USPSTF-STATIN-2022, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Diagnosis, staging and a shared treatment decision within three weeks of the first visit | 1971-06-15 | completed | Biopsy, CT, bone scan and PSMA PET/CT within ten days; apalutamide started at the consultation two weeks after intake | S |
| Bone pain controlled, with a pain score of 2 or less and sleep restored | 1971-07-13 | completed | Pain 6 of 10 at intake, 2 of 10 at four weeks on androgen deprivation | S |
| PSA of 0.2 ng/mL or less within about seven months of starting treatment | 1971-09-14 | completed | PSA 46.8 to 0.18 ng/mL at three months | S |
| Blood pressure below 130/80 mm Hg on androgen deprivation | 1971-10-05 | completed | 152/90 at four weeks on apalutamide; 128/78 at the annual wellness visit on amlodipine 10 mg | S |
| Protect bone health: 25-hydroxyvitamin D of 30 ng/mL or more, calcium from food, weight-bearing exercise, and a bone-protective drug for high fracture risk | 1971-10-05 | active | Denosumab given at four weeks after a dental check; vitamin D 28 ng/mL and rising; walking daily | S |
| Keep his morning writing and his official duties through treatment | 1971-10-05 | completed | Writing every morning; one week of official engagements postponed during radiotherapy | S |